Orexo AB (publ) (ORXOF) Stock

About Orexo AB (publ)

Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.

Orexo AB (publ) is headquartered in SE.

Orexo AB (publ) (ORXOF) stock trades at $1.55 with a market capitalization of $54.45M. The stock is valued at a price-to-earnings (P/E) ratio of -1.65, price-to-book of 1.89, price-to-sales of 3.92. Over the past 52 weeks the stock has ranged between $1.55 and $3.23, and currently trades 52.0% below its 52-week high.

On profitability, Orexo AB (publ) generates a return on equity (ROE) of -136.72%, return on capital employed of -110.01%, an operating margin of -239.92%, a net profit margin of -236.32%.

Official website: www.orexo.com